- Home
- RLYB vs OCX Comparison
RLYB vs OCX Comparison
Compare RLYB & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- OCX
- Stock Information
- Founded
- RLYB 2018
- OCX 2009
- Country
- RLYB United States
- OCX United States
- Employees
- RLYB N/A
- OCX N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RLYB Health Care
- OCX Health Care
- Exchange
- RLYB Nasdaq
- OCX Nasdaq
- Market Cap
- RLYB 42.7M
- OCX 35.1M
- IPO Year
- RLYB 2021
- OCX N/A
- Fundamental
- Price
- RLYB $0.75
- OCX $2.65
- Analyst Decision
- RLYB Buy
- OCX Buy
- Analyst Count
- RLYB 5
- OCX 3
- Target Price
- RLYB $9.75
- OCX $4.42
- AVG Volume (30 Days)
- RLYB 70.1K
- OCX 87.8K
- Earning Date
- RLYB 03-11-2025
- OCX 04-11-2025
- Dividend Yield
- RLYB N/A
- OCX N/A
- EPS Growth
- RLYB N/A
- OCX N/A
- EPS
- RLYB N/A
- OCX N/A
- Revenue
- RLYB $598,000.00
- OCX $709,000.00
- Revenue This Year
- RLYB N/A
- OCX N/A
- Revenue Next Year
- RLYB N/A
- OCX $106.34
- P/E Ratio
- RLYB N/A
- OCX N/A
- Revenue Growth
- RLYB N/A
- OCX N/A
- 52 Week Low
- RLYB $0.73
- OCX $1.92
- 52 Week High
- RLYB $3.46
- OCX $3.48
- Technical
- Relative Strength Index (RSI)
- RLYB 37.62
- OCX 64.49
- Support Level
- RLYB $0.73
- OCX $2.21
- Resistance Level
- RLYB $0.84
- OCX $2.85
- Average True Range (ATR)
- RLYB 0.07
- OCX 0.22
- MACD
- RLYB -0.00
- OCX 0.07
- Stochastic Oscillator
- RLYB 12.89
- OCX 77.90
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.